
Peer reviewed version

Link to published version (if available): 10.1161/CIRCRESAHA.116.309772

Link to publication record in Explore Bristol Research

PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via [insert publisher name] at AHA at http://circres.ahajournals.org/content/119/8/e127. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
TO THE EDITOR:

In the issue of Circulation Research on July 22nd, we published a Mendelian randomization study to assess the causal effect of higher adiponectin levels on the risk of coronary heart disease (CHD) using summary data from large scale genome-wide association studies (GWAS)\(^1\). Overall, our findings are not supportive of the hypothesis that higher adiponectin levels protect against CHD development. In an editorial related to our paper\(^2\), Turer and Scherer state that “Several major issues with the present analysis suggest that the conclusions drawn are rather premature”. In this letter, we discuss the points raised by the authors.

Turer and Scherer point out that one important assumption of Mendelian randomization is that “SNPs significantly influence the levels of adiponectin”\(^2\). Indeed, the use of weak genetic instruments can not only reduce precision, but also introduce bias in Mendelian randomization estimates. For this reason, we selected as genetic instruments the SNPs with the strongest association with adiponectin levels from the largest GWAS available, the ADIPOGen consortium. The SNPs selected nearby the \textit{ADIPOQ} locus, or other highly correlated SNPs, have been previously used in Mendelian randomization studies and explain about 4%-6% of variation in adiponectin levels\(^3,4\). Of note this is a higher proportion of variation than SNPs used in Mendelian randomization studies confirming the causal effect of systolic blood pressure (<1%) on CHD\(^5\). As mentioned in our paper, our instrument for adiponectin gave us more than 97% power to detect an odds ratio of CHD of at least 0.80 per 2.7-fold increment in circulating adiponectin levels, indicating that we would have been able to detect even modest clinically relevant effects.

Regarding concerns over the use of different assays for adiponectin\(^2\). The ADIPOGen consortium included 16 cohorts that measured adiponectin using either RIA or ELISA methods and found highly consistent results when analyses were stratified by type of assay\(^6\). As we noted in our paper, there was little evidence of heterogeneity between studies for most selected SNPs, indicating that study differences, including differences in type of assay, are unlikely to have influenced our results.

Turer and Scherer question whether “randomization was successful in achieving a balance of demographic (...) and clinical characteristics (...)”\(^2\). One of the
core strengths of Mendelian randomization relates to the fact that genetic variants are not usually correlated with confounding factors, as a result of the mechanisms of Mendelian inheritance. This has been demonstrated empirically and is precisely why Mendelian randomization is much less vulnerable to confounding than conventional multivariable regression analysis. The only exception to this would be in the case of population stratification, where confounding could be introduced by subgroups of different genetic ancestries. As mentioned in our paper, the GWAS consortia that contributed to our analyses were largely restricted to individuals of European ancestry and controlled for population stratification by undertaking double genomic control (prior and after meta-analysing results), which is in line with good practices of GWAS. Lastly, we undertook a positive control study using the same CHD data and demonstrated the expected positive causal effect of LDL-c on CHD.

Turer and Scherer are also concerned that by adjusting for some established cardiovascular risk factors we might have over-adjusted for factors on the causal path between adiponectin and CHD. They seem to have misunderstood our methodological approach which set out specifically to explore whether these factors were potential mediators or confounders. First, we showed that SNPs nearby or in the ADIPOQ locus (conservative approach), which codes for adiponectin, were not related to fasting insulin, HDL-c, triacylglycerol, waist circumference or body mass index (Table 2 and Figure 3A). Second, we used a multi-loci set of SNPs (liberal approach) and found that those SNPs outside of the ADIPOQ locus were associated with other CHD risk factors and that the results from MR-Egger method supported the presence of horizontal pleiotropy in the liberal approach. Together these findings strongly suggest that adiponectin does not causally affect these risk factors and therefore they cannot mediate any of its causal effects on disease outcomes. In short, when we used only genetic variants in the ADIPOQ locus only (our conservative approach) combining two extremely large datasets with over 60,000 CHD cases we find the causal odds ratio of a 1 logged unit increase in adiponectin to be 0.97 (95% CI: 0.84, 1.12). There were no adjustments made in these analyses as we had already shown that the variants were not related to other risk factors and therefore these results cannot be ‘over adjusted’.

Although animal studies suggest that adiponectin has cardio-protective effects, the picture has proven to be far more complicated in humans. Findings from
observational epidemiological studies on the association between adiponectin levels and risk of coronary heart disease (CHD) are conflicting and probably biased by residual confounding and reverse causality. Drugs, such as PPAR-γ (peroxisome proliferator-activated receptor gamma) agonists, that lead to changes in adiponectin levels, also act independently on multiple other pathways that likely influence CHD, and, therefore, their metabolic effects cannot be taken as evidence for causal effects of adiponectin. Mendelian randomization has successfully and increasingly been used in clinical research and can be a powerful tool to help unraveling mechanisms of disease and identifying potential drug targets, specially given the complex metabolic phenomena that commonly occur in human diseases. Our study builds on previous Mendelian randomization evidence by showing no consistent protective effect of adiponectin on cardiometabolic diseases.

The editorial by Turer and Scherer concludes that our results ‘should be treated with great caution’. However, we would argue that conclusions based on ‘correlational data’ from human studies, which they present as evidence for cardio-protection, merit the greatest caution, and that ‘preclinical evidence’ from animal studies lacks external validity and should not be assumed to translate to humans. Based on the multiple aspects explored in our analysis and the available evidence, we feel confident concluding that, currently, there is no consistent evidence that circulating adiponectin is more than an epiphenomenon in the context of CHD in humans.

Sources of Funding

MCB received financial support from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (fellowship numbers 144749/2014-9, 201498/2014-6 (Science Without Borders Program), 163291/2015-2) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). DAL works in a Unit that receives funding from the UK Medical Research Council (MC_UU_12013/5) and is a UK National Institute of Health Research Senior Investigator (NF-SI-0611-10196). CO works in the English Longitudinal Study of Ageing (ELSA) that receives funding from the National Institute on Aging in the United States (grant number 5 R01 AG017644-16) and a consortium of UK government departments coordinated by the Office for National Statistics. JW is a UCL core-funded researcher.
Disclosures

None.

References


